The future of acne treatment might look a whole lot different than the range of oral and topical medications currently on ...

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

Over 50 million people across the US live with acne, a condition with no cure that often requires chronic treatment ...

Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...

Sagimet Biosciences (NASDAQ:SGMT) added ~38% in the premarket on Wednesday after the company said its Chinese licensing partner, Ascletis Bioscience, had reached all primary and secondary endpoints in ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, ...

Spanish dermatology specialist Almirall has announced that China’s National Medical Products Administration (NMPA) has ...

Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...